Researchers at Northwestern Medicine have identified immune system markers that may help predict which patients respond to BCG bladder cancer therapy and which do not, according to findings published in the Journal of Clinical Investigation. The discovery could enable physicians to tailor treatment plans more effectively, sparing non-responders from ineffective therapy and its side effects while guiding them toward alternative options.
BCG (Bacillus Calmette-Guérin) therapy is a standard immunotherapy for non-muscle invasive bladder cancer, but it fails in up to 40% of patients. Currently, there is no reliable way to predict who will benefit. The Northwestern team analyzed tumor samples from patients and identified specific immune cell signatures associated with response or resistance. These biomarkers could lead to a clinical test that stratifies patients before treatment begins.
The implications for the industry are significant. Bladder cancer is the sixth most common cancer in the United States, with an estimated 83,190 new cases in 2024. Improving the efficacy of BCG therapy could reduce recurrence rates and lower healthcare costs associated with disease progression. For biotechnology and pharmaceutical companies developing immunotherapies, these biomarkers offer a potential companion diagnostic to enhance clinical trials and patient selection.
Meanwhile, enterprises like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are working to further refine immunotherapy approaches, underscoring the broader push to personalize cancer treatment. The Northwestern study adds to a growing body of research aimed at understanding the immune microenvironment of tumors.
For business leaders and investors, such advances signal a shift toward precision oncology, where biomarkers guide therapy decisions. Companies that can integrate biomarker-driven strategies into their pipelines may gain a competitive edge. Health systems may also benefit by reducing ineffective treatments and improving patient outcomes.
The research was supported by the National Institutes of Health and other institutions. While the findings are promising, the authors note that further validation in larger clinical trials is needed before the biomarkers can be adopted in routine practice.
